Sofía Llorente,Angela Lamarca,Tian V Tian
Sofía Llorente
D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma [0.03%]
Silvia Pedretti,Francesca Palermo,Miriana Braghin et al.
Silvia Pedretti et al.
Sorafenib, a multi-kinase inhibitor for advanced hepatocellular carcinoma (HCC), often encounters resistance within months of treatment, limiting its long-term efficacy. Despite extensive efforts, reliable plasma biomarkers to monitor drug ...
Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma [0.03%]
新型选择性HDAC I/IIb抑制剂甲磺酸Puranostat在复发/难治多发性骨髓瘤和淋巴瘤的临床前及首次人体试验研究
Linyu Yang,Qiang Qiu,Jie Wang et al.
Linyu Yang et al.
Simultaneously targeting key pathogenic drivers and remodeling of the tumor microenvironment represents a critical therapeutic strategy for relapsed or refractory (r/r) multiple myeloma (MM) and lymphoma. Purinostat mesylate (PM), a highly ...
Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors [0.03%]
奥纳西替布联合特瑞普利单抗治疗晚期实体瘤的多中心Ⅰ/Ⅱ期研究
Pei Shu,Xiaoyu Li,Qi Zhou et al.
Pei Shu et al.
Preclinical studies have indicated that the combination of mTORC1/2 inhibitors with PD-1 antibodies exhibits synergistic effects on solid tumors. However, no clinical data supporting this combination have been reported. Therefore, we conduc...
Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma models [0.03%]
MAPK驱动的衰老多组学解析发现了KIAA1549::BRAF融合阳性儿童低级别胶质瘤模型中的治疗弱点
Romain Sigaud,Anja Stefanski,Florian Selt et al.
Romain Sigaud et al.
Pilocytic astrocytomas (PA), the most common pediatric low-grade gliomas (pLGGs), are characterized by genetic MAPK pathway alterations leading to constitutive activation and oncogene-induced senescence (OIS) accompanied with the senescence...
Induced regulatory T cells for therapy: targeting RBPJ to enhance stability and function [0.03%]
针对RBPJ诱导调节性T细胞治疗：增强稳定性和功能
Niklas Beumer,Michael Delacher
Niklas Beumer
Uncovering injury-specific proteomic signatures and neurodegenerative risks in single and repetitive traumatic brain injury [0.03%]
单次和重复性创伤性脑损伤中特异性蛋白质标志物及神经退行性风险的评估
Sarah Mantash,Soulaimane Aboulouard,Hassan Dakik et al.
Sarah Mantash et al.
Traumatic brain injury (TBI) is a major public health concern associated with an increased risk of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and chronic traumatic encephalopathy, yet the underl...
TSC22 domain family member 3 links natural killer cells to CD8+ T cell-mediated drug hypersensitivity [0.03%]
TSC22家族成员3通过自然杀伤细胞将药物超敏反应与CD8⁺T细胞介导的免疫应答联系在一起
Lele Sun,Pengcheng Huai,Zhenzhen Wang et al.
Lele Sun et al.
Severe cutaneous adverse drug reactions (SCARs) are life-threatening diseases, which are associated with human leukocyte antigen (HLA) risk variants. However, the low positive predictive values of HLA variants suggest additional factors inf...
Qilong Li,Tong Liu,Kunying Lv et al.
Qilong Li et al.
Malaria, caused by Plasmodium parasites and transmitted by Anopheles mosquitoes, greatly impacts public health and socioeconomic development, particularly in sub-Saharan African countries. Despite advances in malaria treatment and preventio...
Gerard J Nuovo,Esmerina Tili,Carlo M Croce
Gerard J Nuovo